Test Price
5,500 AED✅ Home Collection Available
OncoPro Comprehensive Cancer Panel (161 Genes) in UAE | 5500 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Executive Summary
The OncoPro Comprehensive Cancer Panel sequences 161 clinically actionable genes from FFPE tumor tissue using Next-Generation Sequencing (NGS) with ISO-accredited bioinformatics. The test delivers 99.9% diagnostic sensitivity for variant detection to guide precision oncology and targeted therapy selection. Logistics rely on Secure Medical Courier Solid Tissue Specimen Retrieval; mobile phlebotomy is not applicable. Post-test telephonic clinical guidance is included, and direct insurance billing verification is available via WhatsApp.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited NGS Processing.
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – hospital extraction only.
- Clinical Guidance: Free Telephonic Post-Test Clinical Guidance with result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The OncoPro panel interrogates the complete coding regions of 161 genes associated with solid tumors. Using Illumina NovaSeq technology, it identifies single nucleotide variants, insertions/deletions, and copy number alterations with high sensitivity. The integrated bioinformatics pipeline classifies variants according to ACMG/AMP guidelines and provides clinically actionable reports for oncologists.
| Feature | Our Test (OncoPro) | Closest Alternative |
|---|---|---|
| Precision | NGS with <1% VAF sensitivity; clinically validated 161-gene panel | Hotspot panels (50-80 genes) lacking full coding regions |
| Methodology | Next-Generation Sequencing (Illumina NovaSeq) + Derived Ratios | Sanger sequencing or limited NGS with manual interpretation |
| Turnaround | 35 Working Days (ISO 15189-controlled workflow) | 40-60 Days, often without UAE lab oversight |
Physician Insight & Safety Protocols
"As a DHA-licensed Specialist Diagnostic Radiology, I recommend correlating the comprehensive genomic profile with the patient's complete clinical and radiological findings. A negative result does not exclude all cancer risks; any actionable mutation must be confirmed through orthogonal methods and discussed in a multidisciplinary tumor board." — Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011)
Medication Warning
Do not discontinue or modify any prescribed cancer therapy without explicit guidance from your treating physician. The test results do not replace clinical judgment.
Exclusion Criteria & Emergency Red Flags
- FFPE block with <10% tumor content may yield insufficient material for analysis; a re-biopsy may be required.
- Known diagnosis of acute leukemia or hematologic malignancy – bone marrow aspirate is the preferred specimen.
- If you experience sudden severe pain, unexplained bleeding, or symptoms suggestive of tumor lysis syndrome, seek emergency medical attention immediately; do not await test results.
Patient FAQ & Clinical Guidance
1. What can the OncoPro 161-gene panel tell me about my cancer?
This test identifies DNA mutations in 161 genes that influence tumor growth, therapy response, and hereditary risk. Results help your oncologist choose targeted treatments, immunotherapies, and clinical trial options relevant to your specific tumor profile.
2. How long does it take to get the results?
Results are issued within 35 working days from the date we receive a suitable FFPE specimen. You will receive digital status updates via our patient app and a secure confidential report link.
3. Is this panel suitable for people without a cancer diagnosis?
The panel is designed for tumor tissue and is primarily used for guiding therapy in diagnosed cancer patients. If hereditary risk assessment is needed without a tumor sample, a separate germline genetic test (e.g., OncoRisk Hereditary Panel) is recommended.
4. How should I prepare for sample collection?
No special preparation is required. The test uses archived FFPE tissue blocks or slides from your previous biopsy or surgery. Your physician will coordinate tissue release with the hospital pathology department. A medical courier will securely transport the specimen to our ISO 15189-accredited laboratory.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This laboratory procedure is performed under DHA Facility License 1143 and complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical data are encrypted, access-controlled, and processed within UAE jurisdiction. Patient consent is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | OncoPro Comprehensive Cancer Panel (161 Genes) |
| Price (AED) | 5,500 AED |
| Turnaround Time | 35 Working Days |
| Sample Type / Matrix | FFPE Tissue Block or Slides (Archival Tissue Specimen – Secure Medical Courier Solid Tissue Specimen Retrieval) |
| Methodology Used | Next-Generation Sequencing (Illumina NovaSeq) with bioinformatics |
| ICD-10-CM Code | C80.1 (Malignant neoplasm, primary site unknown) |
| LOINC Code | 88211-2 (Comprehensive genomic profiling panel - Tissue) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians